Welcome to our dedicated page for Lexicon Pharmaceuticals news (Ticker: LXRX), a resource for investors and traders seeking the latest updates and insights on Lexicon Pharmaceuticals stock.
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) is a biopharmaceutical company whose news flow centers on cardiometabolic and neurological drug development, regulatory interactions and strategic collaborations. The company describes a mission of pioneering medicines that transform patients’ lives, supported by its Genome5000™ genomics platform, which identified more than 100 protein targets with therapeutic potential across multiple diseases.
News about Lexicon frequently highlights clinical data and conference presentations for sotagliflozin, an oral SGLT2 and SGLT1 inhibitor studied in approximately 20,000 patients with heart failure, diabetes and chronic kidney disease. Recent updates include results in heart failure with preserved ejection fraction, ongoing enrollment in the SONATA-HCM Phase 3 study for hypertrophic cardiomyopathy, and work toward regulatory pathways for ZYNQUISTA® in type 1 diabetes.
Investors and healthcare observers can also follow developments in pilavapadin (LX9211) for diabetic peripheral neuropathic pain, where Lexicon has reported Phase 2 and Phase 2b data and End-of-Phase 2 FDA discussions, as well as LX9851, a first-in-class ACSL5 inhibitor for obesity and cardiometabolic disorders licensed to Novo Nordisk. Company news includes licensing milestones, financial results, participation in major healthcare conferences and policy-focused initiatives such as a chronic pain roundtable and white paper on non-opioid treatments.
This LXRX news page aggregates these updates in one place, covering earnings releases, pipeline milestones, regulatory announcements, scientific publications and partnership news drawn from Lexicon’s public statements and SEC filings.
Lexicon Pharmaceuticals (Nasdaq: LXRX) announced on January 21, 2026 that it completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration for pilavapadin in diabetic peripheral neuropathic pain (DPNP).
The FDA raised no objections to advancing pilavapadin into Phase 3, which the company plans as two placebo-controlled, 12-week, two-arm registrational studies evaluating a 10 mg daily dose versus placebo. The Phase 3 primary endpoint will be change in average daily pain score (ADPS) from baseline to Week 12. The FDA did not require unexpected preclinical or clinical studies that would likely delay Phase 3 or a potential regulatory submission.
Viatris (Nasdaq: VTRS) announced the launch of Inpefa (sotagliflozin) in the United Arab Emirates, the first market within Viatris territories to commercialize the drug, with additional launches planned across multiple countries over the next several years.
Inpefa is the first dual SGLT1/2 inhibitor approved to reduce risk of cardiovascular death, heart failure hospitalization, and urgent heart failure visits. Approval is supported by two Phase 3 trials (SOLOIST-WHF and SCORED; >11,800 patients) showing a 33% reduction in the composite endpoint in SOLOIST-WHF (up to 51% when initiated prior to discharge), 25% reduction in SCORED, and a 23% reduction in MACE, including 32% reduction in MI and 34% reduction in stroke.
Lexicon Pharmaceuticals (Nasdaq: LXRX) provided a business and pipeline update at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, and will present on January 15 at 12:00 p.m. PT (3:00 p.m. ET).
Key program timelines: the pivotal SONATA-HCM Phase 3 study of sotagliflozin targets enrollment completion in mid-2026 with topline results expected in Q1 2027. ZYNQUISTA® (sotagliflozin) for type 1 diabetes remains on track for an NDA resubmission and potential approval in 2026 contingent on STENO1 patient exposure and safety data. Pilavapadin advanced via an End-of-Phase 2 meeting and partnership discussions continue.
Commercial and finance: Lexicon triggered a $10 million milestone from Novo Nordisk for LX9851, has received $45 million to date with up to $950 million in remaining milestones plus tiered royalties, and ended 2025 with $125.2 million in cash, investments and restricted cash, which the company says supports operations into 2027 (excluding milestone impacts).
Lexicon Pharmaceuticals (NASDAQ: LXRX) published a white paper titled “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain” summarizing findings from an October 2025 Roundtable of patients, clinicians, advocates, and other stakeholders.
The paper highlights that chronic pain affects one in four American adults, costs the U.S. >$720 billion annually (including ~$190 billion in lost productivity), and calls for swift policy action to expand access to novel non-opioid therapies, citing the recently introduced Relief of Chronic Pain Act.
Lexicon Pharmaceuticals (Nasdaq: LXRX) will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026 at 12:00 p.m. PT / 3:00 p.m. ET in San Francisco.
The company said the live presentation and replay will be available on its investor Events page at https://investors.lexpharma.com/.
Lexicon Pharmaceuticals (Nasdaq: LXRX) announced publication of preclinical data on ACSL5 in the Journal of the Endocrine Society on Dec 10, 2025, reinforcing the rationale for its oral ACSL5 inhibitor LX9851. Animal studies showed ACSL5 knockout mice and mice given potent oral ACSL5 inhibitors had lower body weight and body fat, reduced triglycerides, total cholesterol and blood glucose, and preserved lean mass versus controls.
Mechanistic work linked effects to activation of the ileal brake, which delayed gastric emptying and reduced food intake. Lexicon holds an exclusive worldwide license for LX9851 with Novo Nordisk (March 2025).
Lexicon Pharmaceuticals (Nasdaq: LXRX) will present clinical data on sotagliflozin's effect on adipose tissue distribution in non-diabetic patients with HFpEF at CVCT 2025.
The data derive from SOTA-P-CARDIA, a prospective, randomized, double-blind, placebo-controlled trial conducted by Mount Sinai Medical Center. The presentation is scheduled for Monday, December 8, 2025 at 10:30 a.m. ET and will be delivered by Juan Jose Badimon, Ph.D., at the 22nd Global Cardio Vascular Clinical Trialists Forum (December 8-10, 2025) at the Mayflower Hotel, Washington, D.C.
Lexicon highlighted this dataset alongside recent cardiac remodeling and MACE data as additional evidence of sotagliflozin's differentiated effects versus SGLT2 inhibitors.
Lexicon Pharmaceuticals (Nasdaq: LXRX) said management will participate in two investor conferences in early December 2025: a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 9:00 AM ET and a presentation at the Evercore 8th Annual Healthcare Conference on Thursday, December 4, 2025 at 9:10 AM ET.
Live events and replays will be available on the company’s Events page at https://investors.lexpharma.com/.
Lexicon Pharmaceuticals (Nasdaq: LXRX) announced that company management will participate in a fireside chat at the Jefferies 2025 London Healthcare Conference on Tuesday, November 18, 2025 at 5:00 p.m. GMT (12:00 p.m. EST).
The live event and replay will be available via the company’s Events page on its investor website: https://investors.lexpharma.com/.
Lexicon Pharmaceuticals (Nasdaq: LXRX) reported new clinical data presented at AHA 2025 showing sotagliflozin produced statistically significant improvements in cardiac structure, diastolic function, six-minute walk distance and KCCQ scores in patients with preserved ejection fraction heart failure (HFpEF) without diabetes.
The prospective, randomized, double-blind, placebo-controlled SOTA P CARDIA trial enrolled 88 racially diverse participants (70% female) treated for six months. Peak VO2 improved but did not reach statistical significance. The company highlighted these results as the first demonstration of clinical benefit for HFpEF patients without diabetes.